FDA Flags Wegovy Pill Ad Claims, Novo Nordisk Pares 8.95% Intraday Gain
Novo Nordisk shares rose 8.95% intraday before paring gains after FDA requested changes to promotional claims for its Wegovy obesity pill, flagging potential regulatory hurdles for the new formulation. The agency targeted efficacy statements in the ad, raising marketing compliance questions ahead of the U.S. launch.
1. FDA Flags Wegovy Pill Ad
FDA notified Novo Nordisk that promotional materials for the once-daily Wegovy oral obesity pill contained claims requiring revision, specifically efficacy statements related to average weight loss percentages. The company must amend its ad copy and submit updated evidence to address the agency’s concerns before U.S. launch clearance.
2. Stock Reaction and Outlook
Shares of Novo Nordisk jumped 8.95% intraday following positive sentiment around the Wegovy pill, then pared gains by market close as investors weighed the FDA’s regulatory notice. The regulatory flag underscores potential delays in marketing strategy and could introduce volatility ahead of the new formulation’s commercial rollout.